Los Angeles, California — October 16, 2025 — Leads & Copy — Lunai Bioworks, Inc. (Nasdaq:LNAI) announced today that it has regained compliance with Nasdaq’s minimum bid price requirement. The company’s common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Listing Rule 5550(a)(2), resulting in a notification from Nasdaq Staff on April 14, 2025. Staff has since determined that for the 11 consecutive business days from September 30, 2025 through October 14, 2025, the closing bid price of Lunai Bioworks’ common stock was at or above $1.00 per share.
David Weinstein, Chief Executive Officer, stated that this compliance milestone reflects Lunai Bioworks’ commitment to strategic execution and shareholder value during a transformative period. He added that they remain focused on advancing their AI-powered platform and delivering long-term impact across drug discovery and biodefense.
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
